Lois M Mulligan

Title: The Innovative Contributions of Lois M. Mulligan

Introduction

Lois M. Mulligan is a prominent inventor based in Kingston, CA. She has made significant strides in the field of pharmaceuticals, particularly in the development of cancer treatments. Her work focuses on compounds that inhibit RET kinase, which plays a crucial role in various cancers.

Latest Patents

Mulligan holds a patent for "Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer." This patent describes a class of compounds that are useful in pharmaceutical compositions and methods for treating or preventing cancer. One notable compound, known as cyclobenzaprine and referred to as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 effectively inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. Furthermore, it has been tested in pancreatic cancer, breast cancer, and small cell lung cancer (SCLC) cell lines. The compounds demonstrate utility in inhibiting the survival and proliferation of tumor cells.

Career Highlights

Mulligan's career is marked by her dedication to advancing cancer treatment through innovative research. Her work at Queen's University at Kingston has positioned her as a leader in her field. She has contributed to the understanding of RET inhibitors and their potential applications in oncology.

Collaborations

Mulligan has collaborated with notable colleagues, including Taranjit S. Gujral and Vinay K. Singh. These partnerships have enhanced her research and expanded the impact of her work in the scientific community.

Conclusion

Lois M. Mulligan's contributions to cancer research through her innovative patents and collaborations highlight her role as a key figure in the pharmaceutical industry. Her work continues to pave the way for new treatment options for cancer patients.